Patents by Inventor Hakan Gunaydin

Hakan Gunaydin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KDM5 INHIBITORS
    Publication number: 20200048258
    Abstract: The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: UMAR FARUK MANSOOR, Christian Fischer, Phieng Siliphaivanh, Luis Torres, Hakan Gunaydin, David L. Sloman
  • KDM5 INHIBITORS
    Publication number: 20200048259
    Abstract: The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: UMAR FARUK MANSOOR, Christian Fischer, Phieng Siliphaivanh, Hakan Gunaydin
  • SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20190276438
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 12, 2019
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10344000
    Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 9, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Danielle F. Molinari, Qinglin Pu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20190194186
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 27, 2019
    Inventors: Hongjun Zhang, Kenneth Jay Barr, Blair T. Lapointe, Hakan Gunaydin, Kun Liu, B. Wesley Trotter
  • Substituted indazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10287272
    Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment o RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 14, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10221142
    Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Nunzio Sciammetta, Benjamin Wesley Trotter, Hongjun Zhang, Kenneth J. Barr, John K. F. Maclean, Danielle F. Molinari, Vladimir Simov
  • SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180312489
    Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: November 1, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180305320
    Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: October 25, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Danielle F. Molinari, Qinglin Pu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180016239
    Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 18, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Nunzio Sciammetta, Benjamin Wesley Trotter, Hongjun Zhang, Kenneth J. Barr, John K. F. Maclean, Danielle F. Molinari, Vladimir Simov
  • Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
    Patent number: 9663508
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Amgen Inc.
    Inventors: Howard Bregman, Nagasree Chakka, Erin F. Dimauro, Hua Gao, Hakan Gunaydin, Hongbing Huang, Philip R. Olivieri, Laurie Schenkel, Matthew Weiss
  • Quinazolinone compounds and derivatives thereof
    Patent number: 9505749
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: November 29, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors
    Publication number: 20160214971
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Application
    Filed: October 1, 2014
    Publication date: July 28, 2016
    Applicant: One Amgen Center Drive
    Inventors: Howard BERGMAN, Nagasree CHAKKA, Erin F. DIMAURO, Hau GAO, Hakan GUNAYDIN, Homgbing HUANG, Philip R. OLIVIERI, Laurie SCHENKEL, Matthew WEISS
  • Oxazolidinone compounds and derivatives thereof
    Patent number: 9340549
    Abstract: Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 17, 2016
    Assignee: AMGEN INC.
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Hongbing Huang, Xin Huang, Matthew W. Martin, Vinod F. Patel
  • Quinazolinone Compounds and Derivatives Thereof
    Publication number: 20150225396
    Abstract: Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: August 27, 2013
    Publication date: August 13, 2015
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Xin Huang
  • OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF
    Publication number: 20150045368
    Abstract: Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 12, 2015
    Inventors: Howard Bregman, John L. Buchanan, Nagasree Chakka, Erin F. Dimauro, Hakan Gunaydin, Angel Guzman-Perez, Zihao Hua, Hongbing Huang, Xin Huang, Matthew W. Martin, Vinod F. Patel